Analysts’ Viewpoint
Pulmonary drug delivery is considered as a better alternative to oral delivery. It is being increasingly preferred due to the direct dissemination of drugs to the affected areas. Rise in incidence of chronic respiratory diseases, such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis, is projected to significantly boost the pulmonary drug delivery devices market growth during the forecast period.
Development of smart and digital inhalers and expansion of distribution network due to significant growth of e-commerce sector are likely to offer lucrative pulmonary drug delivery devices market opportunities for manufacturers across the globe. Furthermore, easy availability of pulmonary drug delivery devices in retail pharmacies and e-pharmacies is expected to have a positive impact on the market outlook.
Pulmonary drug delivery systems have been in medical use for over six decades and are employed to administer drugs through the pulmonary route in order to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Growing incidence and awareness about respiratory disorders is leading to advancements in pressurized metered-dose inhalers and integration of nanotechnology in pulmonary drug delivery. This is estimated to drive the demand for inhalation drug administration tools in the near future.
Training and understanding of usage of nasal drug delivery techniques and devices are essential for patients, despite awareness about the benefits breath-activated inhalers. This is expected to hamper the adoption of drug delivery devices. Furthermore, stringent regulatory framework and approval processes are likely to restrain organic growth of the market. Additionally, higher prices of these devices are estimated to further hinder market progress.
Growing pollution and prolonged exposure to harmful gases, tobacco smoke, fumes, and chemicals are key factors driving the prevalence of respiratory diseases. According to the World Health Organization, around 7 million people die every year due to indoor and outdoor pollution, while around 90% of the people breathe polluted air. Therefore, rise in number of deaths occurring due to pulmonary diseases is anticipated to positively impact the market outlook in the next few years.
According to the World Health Organization, in 2019, COPD was the third-leading cause of death, and it led to around 3.23 million deaths across the globe. It further states that the year 2020 recorded over 2.2 million new cases of lung cancer with 1.8 million fatalities. Moreover, around 262 million people across the globe were affected with asthma in 2019, and it caused 461,000 deaths in the same year.
Rapid urbanization and changing lifestyle are key factors driving the prevalence of asthma. Furthermore, surge in awareness about the management of asthma and easy availability of pulmonary drug delivery systems or devices are driving market progress.
Pulmonary drug delivery facilitates direct administration of drugs to the disease site. These devices as highly preferred for patients who may be unable to administer medication through the oral route. Moreover, certain patients have the tendency of through up, or vomit, after intake of medication orally. On the contrary, pulmonary drug delivery facilitates quick onset with negligible systemic side-effects.
In October 2022, Aptar Digital Health strategically partnered with the Chiesi Group to introduce a disease management platform for COPD and asthma. Furthermore, In July 2020, Teva Pharmaceutical Industries Ltd. announced that it had tabled a Bluetooth-enabled version of ProAir albuterol sulfate rescue inhaler. Therefore, integration of technology and advances in pulmonary drug delivery devices are expected to ease administration of doses for patients and consequently, boost their adoption in the near future.
North America accounted for the largest pulmonary drug delivery devices market share in 2022 due to growing incidence of respiratory diseases, such as COPD, allergic rhinitis, and asthma. Additionally, National Asthma Control Program (NACP) from CDC is funding initiatives to create awareness about asthma. This is estimated to boost the adoption of pulmonary medication dispensers in the region.
Rapid urbanization and industrialization in developing economies in Asia Pacific are elevating pollution levels across the region. Increase in pollution is a key factor driving the prevalence of respiratory diseases. This, in turn, is boosting the adoption of respiratory medication delivery devices across the region. Moreover, growing awareness about the safety and convenience involved with pulmonary drug delivery devices is projected to rapidly drive the pulmonary drug delivery devices industry growth in Asia Pacific in the near future.
Leading players in the pulmonary drug delivery devices industry are engaged in various modes of expansion such as new product launch, mergers, acquisitions, partnerships, and joint ventures to consolidate their presence in the global market. Major companies are following the latest pulmonary drug delivery devices market trends to develop advanced devices and cater to customer need worldwide. A few prominent players operating in the global market are AstraZeneca Plc, Novartis AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.
Key players in the pulmonary drug delivery devices market report have been profiled based on various parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 37.2 Bn |
| Market Forecast Value in 2031 | US$ 55.0 Bn |
| Growth Rate (CAGR) | 4.4% |
| Forecast Period | 2023-2031 |
| Quantitative Units | US$ Bn for Value and Million Units for Volume |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape | Prominent Players - Competition Dashboard and Revenue Share Analysis, 2022 Company Profiles (Details - Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview) |
| Regions Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Scope for Customization | Available upon Request |
| Pricing | Available upon Request |
The global market was valued at US$ 37.2 Bn in 2022
It is projected to grow at a CAGR of 4.4% from 2023 to 2031
Rise in prevalence of chronic respiratory diseases and increase in preference for convenience in route of delivery
In terms of distribution channel, the retail pharmacies segment held largest share in 2022
North America is estimated to dominate the global business in the next few years
AstraZeneca Plc, Novartis AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pulmonary Drug Delivery Devices Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value & Volume Forecast, by Product Type, 2023-2031
6.3.1. Dry Powder Inhalers
6.3.2. Metered Dose Inhalers
6.3.3. Nebulizers
6.4. Market Attractiveness, by Product Type
7. Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Application
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value & Volume Forecast, by Application, 2023-2031
7.3.1. Asthma
7.3.2. COPD
7.3.3. Cystic Fibrosis
7.3.4. Others
7.4. Market Attractiveness, by Application
8. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Distribution Channel
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
8.3.1. Retail Pharmacies
8.3.2. Hospital Pharmacies
8.3.3. E-Commerce
8.4. Market Attractiveness, by Distribution Channel
9. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value & Volume Forecast, by Region, 2023-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Pulmonary Drug Delivery Devices Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value & Volume Forecast, by Product Type, 2023-2031
10.2.1. Dry Powder Inhalers
10.2.2. Metered Dose Inhalers
10.2.3. Nebulizers
10.3. Market Attractiveness, by Product Type
10.4. Market Value & Volume Forecast, by Application, 2023-2031
10.4.1. Asthma
10.4.2. COPD
10.4.3. Cystic Fibrosis
10.4.4. Others
10.5. Market Attractiveness, by Application
10.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
10.6.1. Retail Pharmacies
10.6.2. Hospital Pharmacies
10.6.3. E-Commerce
10.7. Market Attractiveness, by Distribution Channel
10.8. Market Value & Volume Forecast, by Country, 2023-2031
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Product Type
10.9.2. By Application
10.9.3. By Distribution Channel
10.9.4. By Country
11. Europe Pulmonary Drug Delivery Devices Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value & Volume Forecast, by Product Type, 2023-2031
11.2.1. Dry Powder Inhalers
11.2.2. Metered Dose Inhalers
11.2.3. Nebulizers
11.3. Market Attractiveness, by Product Type
11.4. Market Value & Volume Forecast, by Application, 2023-2031
11.4.1. Asthma
11.4.2. COPD
11.4.3. Cystic Fibrosis
11.4.4. Others
11.5. Market Attractiveness, by Application
11.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
11.6.1. Retail Pharmacies
11.6.2. Hospital Pharmacies
11.6.3. E-Commerce
11.7. Market Attractiveness, by Distribution Channel
11.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Market Attractiveness Analysis
11.9.1. By Product Type
11.9.2. By Application
11.9.3. By Distribution Channel
11.9.4. By Country/Sub-region
12. Asia Pacific Pulmonary Drug Delivery Devices Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value & Volume Forecast, by Product Type, 2023-2031
12.2.1. Dry Powder Inhalers
12.2.2. Metered Dose Inhalers
12.2.3. Nebulizers
12.3. Market Attractiveness, by Product Type
12.4. Market Value & Volume Forecast, by Application, 2023-2031
12.4.1. Asthma
12.4.2. COPD
12.4.3. Cystic Fibrosis
12.4.4. Others
12.5. Market Attractiveness, by Application
12.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
12.6.1. Retail Pharmacies
12.6.2. Hospital Pharmacies
12.6.3. E-Commerce
12.7. Market Attractiveness, by Distribution Channel
12.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Product Type
12.9.2. By Application
12.9.3. By Distribution Channel
12.9.4. By Country/Sub-region
13. Latin America Pulmonary Drug Delivery Devices Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value & Volume Forecast, by Product Type, 2023-2031
13.2.1. Dry Powder Inhalers
13.2.2. Metered Dose Inhalers
13.2.3. Nebulizers
13.3. Market Attractiveness, by Product Type
13.4. Market Value & Volume Forecast, by Application, 2023-2031
13.4.1. Asthma
13.4.2. COPD
13.4.3. Cystic Fibrosis
13.4.4. Others
13.5. Market Attractiveness, by Application
13.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
13.6.1. Retail Pharmacies
13.6.2. Hospital Pharmacies
13.6.3. E-Commerce
13.7. Market Attractiveness, by Distribution Channel
13.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Product Type
13.9.2. By Application
13.9.3. By Distribution Channel
13.9.4. By Country/Sub-region
14. Middle East & Africa Pulmonary Drug Delivery Devices Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value & Volume Forecast, by Product Type, 2023-2031
14.2.1. Dry Powder Inhalers
14.2.2. Metered Dose Inhalers
14.2.3. Nebulizers
14.3. Market Attractiveness, by Product Type
14.4. Market Value & Volume Forecast, by Application, 2023-2031
14.4.1. Asthma
14.4.2. COPD
14.4.3. Cystic Fibrosis
14.4.4. Others
14.5. Market Attractiveness, by Application
14.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
14.6.1. Retail Pharmacies
14.6.2. Hospital Pharmacies
14.6.3. E-Commerce
14.7. Market Attractiveness, by Distribution Channel
14.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Product Type
14.9.2. By Application
14.9.3. By Distribution Channel
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AstraZeneca Plc
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Novartis AG
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Boehringer Ingelheim GmbH
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. GlaxoSmithKline Plc
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Merck & Co., Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Type Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Teva Pharmaceutical Industries Ltd.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Type Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
List of Tables
Table 01: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 02: Global Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, 2023-2031
Table 03: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 04: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
Table 05: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Region, 2023-2031
Table 06: North America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country, 2023-2031
Table 07: North America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 08: North America Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, 2023-2031
Table 09: North America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 10: North America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
Table 11: Europe Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 12: Europe Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 13: Europe Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, 2023-2031
Table 14: Europe Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 15: Europe Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel 2023-2031
Table 16: Asia Pacific Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 17: Asia Pacific Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 18: Asia Pacific Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, 2023-2031
Table 19: Asia Pacific Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 20: Asia Pacific Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
Table 21: Latin America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 22: Latin America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 23: Latin America Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, 2023-2031
Table 24: Latin America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 25: Latin America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel 2023-2031
Table 26: Middle East & Africa Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 27: Middle East & Africa Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 28: Latin America Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, 2023-2031
Table 29: Middle East & Africa Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 30: Middle East & Africa Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel 2023-2031
List of Figures
Figure 01: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, 2023-2031
Figure 02: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 03: Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 04: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2022 and 2031
Figure 05: Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Application, 2023-2031
Figure 06: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 07: Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel 2023-2031
Figure 08: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Region, 2022 and 2031
Figure 09: Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Region, 2023-2031
Figure 10: North America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, 2023-2031
Figure 11: North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 12: North America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 13: North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2022 and 2031
Figure 14: North America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Application, 2023-2031
Figure 15: North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 16: North America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel 2023-2031
Figure 17: North America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Country, 2022 and 2031
Figure 18: North America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Country, 2023-2031
Figure 19: Europe Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, 2023-2031
Figure 20: Europe Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 21: Europe America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 22: Europe Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2022 and 2031
Figure 23: Europe Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Application, 2023-2031
Figure 24: Europe Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 25: Europe Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel 2023-2031
Figure 26: Europe Pulmonary Drug Delivery Devices Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 27: Europe Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 28: Asia Pacific Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, 2023-2031
Figure 29: Asia Pacific Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 30: Asia Pacific America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 31: Asia Pacific Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2022 and 2031
Figure 32: Asia Pacific Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Application, 2023-2031
Figure 33: Asia Pacific Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 34: Asia Pacific Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel 2023-2031
Figure 35: Asia Pacific Pulmonary Drug Delivery Devices Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Asia Pacific Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 37: Latin America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, 2023-2031
Figure 38: Latin America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 39: Latin America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 40: Latin America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2022 and 2031
Figure 41: Latin America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Application, 2023-2031
Figure 42: Latin America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 43: Latin America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 44: Latin America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 45: Latin America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 46: Middle East & Africa Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, 2023-2031
Figure 47: Middle East & Africa America Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type, 2023-2031
Figure 48: Middle East & Africa America Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 49: Middle East & Africa Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 50: Middle East & Africa Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel 2023-2031
Figure 51: Middle East & Africa Pulmonary Drug Delivery Devices Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 52: Middle East & Africa Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 53: Global Pulmonary Drug Delivery Devices Market Share Analysis, by Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pulmonary Drug Delivery Devices Market
